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Tamoxifen is a nonsteroidal anti-oestrogen that is widely
prescribed to breast cancer patients either as palliative therapy in
metastatic disease or as adjuvant therapy. In current trials in the
UK, USA and Italy, the value of tamoxifen for the prevention of
breast cancer in high-risk women is also investigated (Powles et al,
1994; Fisher and Redmond, 1991). Over the last decade concern
about the side-effects of tamoxifen has focused mainly on
the occurrence of endometrial carcinoma with a 2.3–6.4-fold
increased risk compared to non-using patients (Fornander et al,
1989; Andersson et al, 1991; Van Leeuwen et al, 1994). Ovarian
cyst formation during tamoxifen has been reported in single cases
(Jolles et al, 1990; Barbieri et al, 1993; Seoud et al, 1993; Terada et
al, 1993; Cohen et al, 1994; Shulman et al, 1994; Re et al, 1994),
in a breast cancer prevention study (Powles et al, 1994) and in
series of tamoxifen-treated breast cancer patients (Boccardo et al,
1992; Cohen et al, 1996; Shushan et al, 1996). However, it is
unclear which patients are prone to develop ovarian cysts and if
the presence of cysts is of any clinical relevance.
The present study was undertaken to evaluate parameters deter-
mining ovarian cyst formation. Patient characteristics like age, last
menstrual period, previous chemotherapy, duration of tamoxifen
use and serum E2 and FSH levels were related to the occurrence of
ovarian cysts.
MATERIALS AND METHODS
A cross-sectional study was performed in pre- and post-
menopausal breast cancer patients using tamoxifen. Patients from
the Departments of Medical Oncology and Radiotherapy of the
University Hospital in Groningen, the Netherlands were referred
during tamoxifen treatment to the Department of Gynaecology, as
part of a gynaecological screening programme for women using
tamoxifen. Based on previous chemotherapy, three different
patient groups were defined. Patients in groups A and B partici-
pated in a randomized trial comparing the efficacy of intensive
adjuvant chemotherapy: group A had five cycles of standard dose
FEC (5-fluorouracil, epirubicin and cyclophosphamide) and group
B had four cycles of standard dose FEC and one cycle of high-dose
chemotherapy (cyclophosphamide, thiotepa and carboplatin),
followed by reinfusion of peripheral haematopoietic stem cells. In
both groups, chemotherapy was followed by 2 years of tamoxifen.
In group C, patients with advanced breast cancer were treated with
tamoxifen without previous chemotherapy. Forty-five patients 
also underwent a gynaecological assessment, TVU and serum
sampling prior to starting tamoxifen treatment. After the first visit
all patients were seen for follow-up twice a year.
A gynaecological history was taken with emphasis on menstrual
pattern and last menstrual period. After pelvic examination, all
patients underwent transvaginal ultrasonography (TVU) using an
Aloka 620 with a 5.0 MHz transvaginal transducer (Aloka, Tokyo,
Japan). The same physician performed all examinations. Both
ovaries were scanned and measured, counting and measuring
individual ovarian cysts in three directions. Cysts were defined as
sonolucencies in the ovary with a mean diameter of ³ 30 mm
(Granberg et al, 1989). Uterine size and endometrial thickness
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serum samples were obtained. Serum FSH levels were determined
by radioimmunoassay (Amerlite FSH Assay, Johnson & Johnson
Clinical Diagnostics Ltd, Amersham, UK). For E2 measurement
an in-house radioimmunoassay was used as described previously
(Jurjens et al, 1975). Normal values in premenopause for FSH
are 0.5–10.0 IU l–1 and for E2 are 0.07–1.00 nmol l–1, excluding
midcycle peaks. Normal postmenopausal values are for FSH 
> 30 IU l–1 and for E2 < 0.10 nmol 1–1 (Speroff et al, 1994).
Statistics
Statistical analysis of the distribution of clinical and hormonal
parameters in the two patient groups was performed with the
Mann-Whitney U-test for unpaired samples. Frequency tables
were analysed using the Fisher’s exact or Chi-square test with
Yates’ correction for small numbers. Rank order correlations were
calculated by the method of Spearman. To determine the impor-
tance of different patient parameters for ovarian cyst formation




Between January 1995 and October 1997, 142 consecutive breast
cancer patients were referred to the gynaecology outpatient clinic.
Patient characteristics at referral are summarized in Table 1. One
hundred and seventeen patients (82%) received tamoxifen in a
daily dose of 40 mg and 111/142 (78%) received previous
chemotherapy. Forty-five patients (32%) were also examined
before starting tamoxifen treatment.
No cyst-related complaints were recorded. Uni- or bilateral
ovarian cysts were detected by TVU in 25 patients which could
be palpated in 16 patients. Patient characteristics in relation to
ovarian cyst formation are summarized in Table 2. Of the 25 cystic
ovaries, 24 were detected in 142 patients using tamoxifen (17%),
and one in 45 patients before tamoxifen treatment was started
(2.2%) (P < 0.001). The mean diameter of the ovarian cysts varied
from 31 mm to 61 mm and all had a benign aspect according to the
criteria described by Granberg et al (1989). During follow-up the
cysts either increased (32%) or decreased (36%) in size or they
disappeared completely (32%). During the study, new cysts
developed in the contralateral ovary in 41%. No medical or
surgical intervention was indicated in any patient.
All cystic ovaries appeared in patients with a last menstrual
period within 1 year (24/67 (36%)) and no cysts were found in
patients with an amenorrhoea > 1 year (0/75 (0%)). Sixteen out
of 142 tamoxifen-using patients not only had their last period
less than 1 year ago but also maintained menstrual cycles during
tamoxifen treatment. Thirteen (81%) of these patients developed
ovarian cysts. All patients who had received high-dose
chemotherapy became amenorrhoeic and no ovarian cysts devel-
oped in this group. Patients with ovarian cysts were younger
(P < 0.05) and had a shorter period of amenorrhoea (P < 0.001)
(Table 2). No cysts occurred in patients > 50 years. No relation
was observed between dose or duration of tamoxifen use and the
appearance of ovarian cysts.
Patients with cysts had higher serum E2 levels (1.95 nmol l–1)
than patients without cysts (0.05 nmol l–1; P < 0.001). Multiple
regression analysis showed that ovarian cyst formation is related
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Table 1 Patient characteristics
All patients Group A Group B Group C
(n = 142) (n = 64) (n = 50) (n = 28)
Age in years median (range) 48 (24–86) 45 (27–56) 46 (24–54) 60 (44–86)
Previous chemotherapy
5 ´ FEC 64 64 – –
4 ´ FEC + high-dose 50 – 50 –
No chemotherapy 28 – – 28
Tamoxifen dose
20 mg day–1 25 4 1 20
40 mg day–1 117 60 49 8
Duration of amenorrhoea
≤ 1 year 67 41 22 4
> 1 year 75 23 28 24
Ovarian cysts
Yes 24 20 1 3
N o 1 1 8 4 44 92 5
Table 2 Ovarian cyst formation in tamoxifen users in relation to patient characteristics
No cysts Cysts P value
Number of patients 118 24
Age in years (range) 50 (24–86) 38 (27–50) < 0.05
Amenorrhoea duration in months (range) 24 (1–430) 1 (1–11) < 0.001
Number of patients with amenorrhoea ≤ 1 yr 43 25 < 0.001
Tamoxifen use in months (range) 7 (0–92) 5 (0–79) N.S.
E2 nmol l–1 (range) 0.05 (0–1.27) 1.95 (0.17–4.8) < 0.001
FSH IU l–1 (range) 22.5 (7.8–51.2) 12.8 (3.1–44.4) N.S.(multiple R = 0.73) to high E2 levels (P < 0.001), no previous
high-dose chemotherapy (P = 0.007), and younger age (< 50 years;
P < 0.001). These three parameters are associated, however.
In the 45 patients who were examined before the start of tamox-
ifen treatment, one ovarian cyst was detected in a 33-year-old
patient who had received five cycles of standard dose FEC. After
the patient started with tamoxifen the ovarian cyst first increased,
later decreased in size and a new cyst developed in the contra-
lateral ovary. After 2 years of tamoxifen treatment both cysts
disappeared spontaneously.
DISCUSSION
Tamoxifen is a nonsteroidal anti-oestrogen which has proven to be
effective in the treatment of early and metastatic breast cancer (Early
Breast Cancer Trialists’ Collaborative Group, 1992; Santen et al,
1990). The present study shows that in patients with residual ovarian
function, as defined by E2 levels  ³ 0.10 nmol l–1, tamoxifen can
result in ovarian cyst formation. Ovarian cysts appeared in
36% of tamoxifen-using patients with amenorrhoea of ≤ 1 year.
Apparently, ovarian cysts occurred only in functional ovaries as
13/16 patients (81%) with menstrual periods during tamoxifen treat-
ment developed ovarian cysts, against no patients with amenorrhoea
of more than 1 year. All patients who had received high-dose
chemotherapy developed amenorrhoea and low E2 (< 0.10 nmol l–1)
while no ovarian cysts were found in these patients. The results of
the randomized trial comparing the efficacy of adjuvant standard-
dose and high-dose chemotherapy in women ≤ 55 years of age are
not yet available. Our findings of complete and permanent amenor-
rhoea in premenopausal patients treated with high-dose regimens
might become one of the possible factors involved, if a difference in
clinical outcome would be observed (Bines et al, 1996).
In a recent study by Cohen et al (1996), 16 out of 175 post-
menopausal breast cancer patients treated with tamoxifen under-
went salpingo-oophorectomy for various reasons. In 10 out of
these 16 postmenopausal patients, ovarian enlargement was found
during surgery. TVU prior to surgery detected ovarian cysts in
seven. Pathologic examination showed benign cysts, cystade-
nomas, metastatic breast cancer in two and endometroid adeno-
carcinoma in one. No serum hormone levels were reported in this
study. A direct relation between the variety of ovarian pathology
and previous tamoxifen in this study is debatable. In the present
study, no cysts were detected in postmenopausal patients. In a
placebo controlled tamoxifen chemoprevention trial in 1054
healthy pre- and postmenopausal women (Powles et al, 1994)
TVU demonstrated a significantly increased risk of ovarian cysts
in premenopausal women who had received tamoxifen for more
than 3 months. No change was found in ovarian appearances in
postmenopausal women.
In the first GROCTA (Breast Cancer Adjuvant Chemo-hormone
Therapy Cooperative Group) trial, three ovarian cysts were
detected in 79 premenopausal patients on tamoxifen and no cysts
in postmenopausal women or patients treated with chemotherapy
(n = 165) or a combination of both treatments (n = 171) (Boccardo
et al, 1992). Neither in the Royal Marsden Study nor in the
GROCTA trial were data provided on hormonal status.
Our study shows that the effects of tamoxifen in premenopausal
women differ from those observed in postmenopausal women. In
premenopausal women tamoxifen use can result in ovarian cysts
and possibly multiple ovulations. Data from both epidemiological
and in vitro studies point to a link between incessant ovulation
and malignant ovarian transformation (Wittemore et al, 1992). The
long-term (> 1 year) use of clomiphene, another anti-oestrogen
with poly-ovulatory effects on the ovaries (Gerhard and
Runnebaum, 1979), has been linked to a higher risk of malignant
ovarian tumours (Rossing et al, 1994). Current cancer prevention
trials are predominantly performed in premenopausal women who
are at increased risk of developing breast cancer. Some of these
women will be carriers of a mutated BRCA1 or BRCA2 gene and
are therefore also at risk of developing ovarian cancer (Shattuck-
Eidens et al, 1995). Recently, a protective effect of oral contracep-
tive agents against ovarian cancer was recognized in BRCA1 and
BRCA2 gene mutation carriers (Narod et al, 1998), most probably
due to the inhibition of ovulation. Hypothetically, ovarian hyper-
stimulation by tamoxifen might have the opposite effect. Although
tamoxifen has been prescribed to many premenopausal women
since its approval, less premenopausal than postmenopausal
patients have been treated with tamoxifen and the fact that no
increased incidence of ovarian cancer has been reported thus far is
therefore not completely reassuring (Spicer et al, 1991). In carriers
of a mutated BRCA1 or BRCA2 gene ovarian enlargement may
present a dilemma to the clinician.
In the present study, the ovarian cysts were all asymptomatic and
had a benign ultrasonographic aspect. Follow-up of the cysts
showed that they disappeared in time or (in one patient) after discon-
tinuation of tamoxifen. Therefore, no medical or surgical interven-
tion was indicated in our study population. However, complications
of ovarian cysts such as ovarian torsion (Barbieri et al, 1993) and
necrosis (Jolles et al, 1990) have been described in tamoxifen
users. As the indications for tamoxifen use have increased and
include preventative therapy for high-risk women, many healthy
premenopausal women will be using tamoxifen in the near future.
This study shows that cysts in tamoxifen-using breast cancer
patients develop only if their ovaries are able to respond to
tamoxifen as indicated by E2 production. Patients with menstrual
periods during tamoxifen treatment have a high chance of devel-
oping ovarian cysts. We did not find any clinical consequences of
the development of ovarian cysts in premenopausal women treated
with tamoxifen in this study. However, awareness is warranted in
those premenopausal women who are at increased risk of ovarian
cancer because of BRCA1 or BRCA2 gene mutation.
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